THROMB HAEMOSTASIS 润色咨询

THROMBOSIS AND HAEMOSTASIS

出版年份:1976 年文章数:2530 投稿命中率: 开通期刊会员,数据随心看

出版周期:Monthly 自引率:10.9% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2215159, encodeId=9ade22151598a, content=从awaiting reviewer assignment直接变成awaiting EIC decision,没有收到审稿人的意见就变成主编决定了,很忐忑呐!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc729386750, createdName=ms6000000193292497, createdTime=Mon Jul 15 23:19:18 CST 2024, time=2024-07-15, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2215155, encodeId=63d2221515568, content=有朋友遇到过从awaiting reviewer assignment 直接变成awaiting EIC decision 的情况吗?按理来说应该是要分配审稿人的,但是没有收到审稿意见直接变成主编决定,非常忐忑不安呐!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ae25440471, createdName=ms7000002143451046, createdTime=Mon Jul 15 23:08:07 CST 2024, time=2024-07-15, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2176663, encodeId=f7c121e666302, content=awaiting reviewer scores 后11天后变成了Awaiting SE Recommendation ,拒的可能性大吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bbb4799156, createdName=2606467171, createdTime=Sat Dec 23 10:23:14 CST 2023, time=2023-12-23, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1216555, encodeId=ba5d121655554, content=投稿命中率:25.0<br>偏重的研究方向:血液<br>经验分享:我投稿8天了,依然处于Awaiting Admin Processing,稿号TH-22-04-0201<br>不知道是否正常,你们都啥情况?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b2e2216153, createdName=120e7c52m79(暂无昵称), createdTime=Tue May 03 14:04:00 CST 2022, time=2022-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224943, encodeId=bede122494364, content=投稿命中率:50.0<br>偏重的研究方向:心血管医学<br>经验分享:5月24号投稿,到现在Awaiting EIC Decision已经快10天了,是不是没戏了。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc5b5422035, createdName=ms8000000183735007, createdTime=Tue Jun 07 12:45:03 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2166341, encodeId=fbc72166341ba, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:静脉血栓;孟德尔随机化<br>经验分享:Submit:30-Jul-2023<br>Major Revision:27-Aug-2023<br>Minor Revision:18-Oct-2023<br>Accept:26-Oct-2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220102/e596621ff7ca4602b0af813517c72811/c6ec383c45484fd78c6ed80849d0e129.jpg, createdBy=81935632595, createdName=一步之遥、, createdTime=Thu Nov 02 18:29:17 CST 2023, time=2023-11-02, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1098101, encodeId=ebeb109810186, content=模型图对审稿人对稿件的态度是有利还是不利?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098102, encodeId=0f67109810229, content=实验数据被抢先发表了怎么办?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=839911, encodeId=0f558399117c, content=2次大修后再一次小修,小修返回后第二天被接收了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dee5413979, createdName=ms4391593229390302, createdTime=Fri Dec 15 19:21:28 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548925, encodeId=fa0554892581, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:一审一个月,共两个Review,审稿人意见比较苛刻,重视体内数据和临床意义,是ESC血栓和动脉粥样硬化工作组的官方杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=367, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da2b2190065, createdName=peterread, createdTime=Sun Nov 05 18:26:00 CST 2017, time=2017-11-05, status=1, ipAttribution=)]
    2024-07-15 ms6000000193292497 来自四川省

    从awaiting reviewer assignment直接变成awaiting EIC decision,没有收到审稿人的意见就变成主编决定了,很忐忑呐!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2215159, encodeId=9ade22151598a, content=从awaiting reviewer assignment直接变成awaiting EIC decision,没有收到审稿人的意见就变成主编决定了,很忐忑呐!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc729386750, createdName=ms6000000193292497, createdTime=Mon Jul 15 23:19:18 CST 2024, time=2024-07-15, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2215155, encodeId=63d2221515568, content=有朋友遇到过从awaiting reviewer assignment 直接变成awaiting EIC decision 的情况吗?按理来说应该是要分配审稿人的,但是没有收到审稿意见直接变成主编决定,非常忐忑不安呐!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ae25440471, createdName=ms7000002143451046, createdTime=Mon Jul 15 23:08:07 CST 2024, time=2024-07-15, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2176663, encodeId=f7c121e666302, content=awaiting reviewer scores 后11天后变成了Awaiting SE Recommendation ,拒的可能性大吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bbb4799156, createdName=2606467171, createdTime=Sat Dec 23 10:23:14 CST 2023, time=2023-12-23, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1216555, encodeId=ba5d121655554, content=投稿命中率:25.0<br>偏重的研究方向:血液<br>经验分享:我投稿8天了,依然处于Awaiting Admin Processing,稿号TH-22-04-0201<br>不知道是否正常,你们都啥情况?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b2e2216153, createdName=120e7c52m79(暂无昵称), createdTime=Tue May 03 14:04:00 CST 2022, time=2022-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224943, encodeId=bede122494364, content=投稿命中率:50.0<br>偏重的研究方向:心血管医学<br>经验分享:5月24号投稿,到现在Awaiting EIC Decision已经快10天了,是不是没戏了。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc5b5422035, createdName=ms8000000183735007, createdTime=Tue Jun 07 12:45:03 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2166341, encodeId=fbc72166341ba, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:静脉血栓;孟德尔随机化<br>经验分享:Submit:30-Jul-2023<br>Major Revision:27-Aug-2023<br>Minor Revision:18-Oct-2023<br>Accept:26-Oct-2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220102/e596621ff7ca4602b0af813517c72811/c6ec383c45484fd78c6ed80849d0e129.jpg, createdBy=81935632595, createdName=一步之遥、, createdTime=Thu Nov 02 18:29:17 CST 2023, time=2023-11-02, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1098101, encodeId=ebeb109810186, content=模型图对审稿人对稿件的态度是有利还是不利?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098102, encodeId=0f67109810229, content=实验数据被抢先发表了怎么办?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=839911, encodeId=0f558399117c, content=2次大修后再一次小修,小修返回后第二天被接收了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dee5413979, createdName=ms4391593229390302, createdTime=Fri Dec 15 19:21:28 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548925, encodeId=fa0554892581, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:一审一个月,共两个Review,审稿人意见比较苛刻,重视体内数据和临床意义,是ESC血栓和动脉粥样硬化工作组的官方杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=367, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da2b2190065, createdName=peterread, createdTime=Sun Nov 05 18:26:00 CST 2017, time=2017-11-05, status=1, ipAttribution=)]
    2024-07-15 ms7000002143451046 来自四川省

    有朋友遇到过从awaiting reviewer assignment 直接变成awaiting EIC decision 的情况吗?按理来说应该是要分配审稿人的,但是没有收到审稿意见直接变成主编决定,非常忐忑不安呐!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2215159, encodeId=9ade22151598a, content=从awaiting reviewer assignment直接变成awaiting EIC decision,没有收到审稿人的意见就变成主编决定了,很忐忑呐!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc729386750, createdName=ms6000000193292497, createdTime=Mon Jul 15 23:19:18 CST 2024, time=2024-07-15, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2215155, encodeId=63d2221515568, content=有朋友遇到过从awaiting reviewer assignment 直接变成awaiting EIC decision 的情况吗?按理来说应该是要分配审稿人的,但是没有收到审稿意见直接变成主编决定,非常忐忑不安呐!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ae25440471, createdName=ms7000002143451046, createdTime=Mon Jul 15 23:08:07 CST 2024, time=2024-07-15, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2176663, encodeId=f7c121e666302, content=awaiting reviewer scores 后11天后变成了Awaiting SE Recommendation ,拒的可能性大吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bbb4799156, createdName=2606467171, createdTime=Sat Dec 23 10:23:14 CST 2023, time=2023-12-23, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1216555, encodeId=ba5d121655554, content=投稿命中率:25.0<br>偏重的研究方向:血液<br>经验分享:我投稿8天了,依然处于Awaiting Admin Processing,稿号TH-22-04-0201<br>不知道是否正常,你们都啥情况?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b2e2216153, createdName=120e7c52m79(暂无昵称), createdTime=Tue May 03 14:04:00 CST 2022, time=2022-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224943, encodeId=bede122494364, content=投稿命中率:50.0<br>偏重的研究方向:心血管医学<br>经验分享:5月24号投稿,到现在Awaiting EIC Decision已经快10天了,是不是没戏了。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc5b5422035, createdName=ms8000000183735007, createdTime=Tue Jun 07 12:45:03 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2166341, encodeId=fbc72166341ba, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:静脉血栓;孟德尔随机化<br>经验分享:Submit:30-Jul-2023<br>Major Revision:27-Aug-2023<br>Minor Revision:18-Oct-2023<br>Accept:26-Oct-2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220102/e596621ff7ca4602b0af813517c72811/c6ec383c45484fd78c6ed80849d0e129.jpg, createdBy=81935632595, createdName=一步之遥、, createdTime=Thu Nov 02 18:29:17 CST 2023, time=2023-11-02, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1098101, encodeId=ebeb109810186, content=模型图对审稿人对稿件的态度是有利还是不利?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098102, encodeId=0f67109810229, content=实验数据被抢先发表了怎么办?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=839911, encodeId=0f558399117c, content=2次大修后再一次小修,小修返回后第二天被接收了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dee5413979, createdName=ms4391593229390302, createdTime=Fri Dec 15 19:21:28 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548925, encodeId=fa0554892581, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:一审一个月,共两个Review,审稿人意见比较苛刻,重视体内数据和临床意义,是ESC血栓和动脉粥样硬化工作组的官方杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=367, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da2b2190065, createdName=peterread, createdTime=Sun Nov 05 18:26:00 CST 2017, time=2017-11-05, status=1, ipAttribution=)]
    2023-12-23 2606467171 来自四川省

    awaiting reviewer scores 后11天后变成了Awaiting SE Recommendation ,拒的可能性大吗?

    15

    展开15条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2215159, encodeId=9ade22151598a, content=从awaiting reviewer assignment直接变成awaiting EIC decision,没有收到审稿人的意见就变成主编决定了,很忐忑呐!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc729386750, createdName=ms6000000193292497, createdTime=Mon Jul 15 23:19:18 CST 2024, time=2024-07-15, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2215155, encodeId=63d2221515568, content=有朋友遇到过从awaiting reviewer assignment 直接变成awaiting EIC decision 的情况吗?按理来说应该是要分配审稿人的,但是没有收到审稿意见直接变成主编决定,非常忐忑不安呐!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ae25440471, createdName=ms7000002143451046, createdTime=Mon Jul 15 23:08:07 CST 2024, time=2024-07-15, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2176663, encodeId=f7c121e666302, content=awaiting reviewer scores 后11天后变成了Awaiting SE Recommendation ,拒的可能性大吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bbb4799156, createdName=2606467171, createdTime=Sat Dec 23 10:23:14 CST 2023, time=2023-12-23, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1216555, encodeId=ba5d121655554, content=投稿命中率:25.0<br>偏重的研究方向:血液<br>经验分享:我投稿8天了,依然处于Awaiting Admin Processing,稿号TH-22-04-0201<br>不知道是否正常,你们都啥情况?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b2e2216153, createdName=120e7c52m79(暂无昵称), createdTime=Tue May 03 14:04:00 CST 2022, time=2022-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224943, encodeId=bede122494364, content=投稿命中率:50.0<br>偏重的研究方向:心血管医学<br>经验分享:5月24号投稿,到现在Awaiting EIC Decision已经快10天了,是不是没戏了。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc5b5422035, createdName=ms8000000183735007, createdTime=Tue Jun 07 12:45:03 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2166341, encodeId=fbc72166341ba, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:静脉血栓;孟德尔随机化<br>经验分享:Submit:30-Jul-2023<br>Major Revision:27-Aug-2023<br>Minor Revision:18-Oct-2023<br>Accept:26-Oct-2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220102/e596621ff7ca4602b0af813517c72811/c6ec383c45484fd78c6ed80849d0e129.jpg, createdBy=81935632595, createdName=一步之遥、, createdTime=Thu Nov 02 18:29:17 CST 2023, time=2023-11-02, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1098101, encodeId=ebeb109810186, content=模型图对审稿人对稿件的态度是有利还是不利?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098102, encodeId=0f67109810229, content=实验数据被抢先发表了怎么办?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=839911, encodeId=0f558399117c, content=2次大修后再一次小修,小修返回后第二天被接收了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dee5413979, createdName=ms4391593229390302, createdTime=Fri Dec 15 19:21:28 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548925, encodeId=fa0554892581, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:一审一个月,共两个Review,审稿人意见比较苛刻,重视体内数据和临床意义,是ESC血栓和动脉粥样硬化工作组的官方杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=367, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da2b2190065, createdName=peterread, createdTime=Sun Nov 05 18:26:00 CST 2017, time=2017-11-05, status=1, ipAttribution=)]
    2022-05-03 120e7c52m79(暂无昵称)

    投稿命中率:25.0
    偏重的研究方向:血液
    经验分享:我投稿8天了,依然处于Awaiting Admin Processing,稿号TH-22-04-0201
    不知道是否正常,你们都啥情况?

    3

    展开3条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2215159, encodeId=9ade22151598a, content=从awaiting reviewer assignment直接变成awaiting EIC decision,没有收到审稿人的意见就变成主编决定了,很忐忑呐!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc729386750, createdName=ms6000000193292497, createdTime=Mon Jul 15 23:19:18 CST 2024, time=2024-07-15, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2215155, encodeId=63d2221515568, content=有朋友遇到过从awaiting reviewer assignment 直接变成awaiting EIC decision 的情况吗?按理来说应该是要分配审稿人的,但是没有收到审稿意见直接变成主编决定,非常忐忑不安呐!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ae25440471, createdName=ms7000002143451046, createdTime=Mon Jul 15 23:08:07 CST 2024, time=2024-07-15, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2176663, encodeId=f7c121e666302, content=awaiting reviewer scores 后11天后变成了Awaiting SE Recommendation ,拒的可能性大吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bbb4799156, createdName=2606467171, createdTime=Sat Dec 23 10:23:14 CST 2023, time=2023-12-23, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1216555, encodeId=ba5d121655554, content=投稿命中率:25.0<br>偏重的研究方向:血液<br>经验分享:我投稿8天了,依然处于Awaiting Admin Processing,稿号TH-22-04-0201<br>不知道是否正常,你们都啥情况?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b2e2216153, createdName=120e7c52m79(暂无昵称), createdTime=Tue May 03 14:04:00 CST 2022, time=2022-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224943, encodeId=bede122494364, content=投稿命中率:50.0<br>偏重的研究方向:心血管医学<br>经验分享:5月24号投稿,到现在Awaiting EIC Decision已经快10天了,是不是没戏了。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc5b5422035, createdName=ms8000000183735007, createdTime=Tue Jun 07 12:45:03 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2166341, encodeId=fbc72166341ba, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:静脉血栓;孟德尔随机化<br>经验分享:Submit:30-Jul-2023<br>Major Revision:27-Aug-2023<br>Minor Revision:18-Oct-2023<br>Accept:26-Oct-2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220102/e596621ff7ca4602b0af813517c72811/c6ec383c45484fd78c6ed80849d0e129.jpg, createdBy=81935632595, createdName=一步之遥、, createdTime=Thu Nov 02 18:29:17 CST 2023, time=2023-11-02, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1098101, encodeId=ebeb109810186, content=模型图对审稿人对稿件的态度是有利还是不利?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098102, encodeId=0f67109810229, content=实验数据被抢先发表了怎么办?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=839911, encodeId=0f558399117c, content=2次大修后再一次小修,小修返回后第二天被接收了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dee5413979, createdName=ms4391593229390302, createdTime=Fri Dec 15 19:21:28 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548925, encodeId=fa0554892581, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:一审一个月,共两个Review,审稿人意见比较苛刻,重视体内数据和临床意义,是ESC血栓和动脉粥样硬化工作组的官方杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=367, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da2b2190065, createdName=peterread, createdTime=Sun Nov 05 18:26:00 CST 2017, time=2017-11-05, status=1, ipAttribution=)]
    2022-06-07 ms8000000183735007

    投稿命中率:50.0
    偏重的研究方向:心血管医学
    经验分享:5月24号投稿,到现在Awaiting EIC Decision已经快10天了,是不是没戏了。

    3

    展开3条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2215159, encodeId=9ade22151598a, content=从awaiting reviewer assignment直接变成awaiting EIC decision,没有收到审稿人的意见就变成主编决定了,很忐忑呐!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc729386750, createdName=ms6000000193292497, createdTime=Mon Jul 15 23:19:18 CST 2024, time=2024-07-15, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2215155, encodeId=63d2221515568, content=有朋友遇到过从awaiting reviewer assignment 直接变成awaiting EIC decision 的情况吗?按理来说应该是要分配审稿人的,但是没有收到审稿意见直接变成主编决定,非常忐忑不安呐!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ae25440471, createdName=ms7000002143451046, createdTime=Mon Jul 15 23:08:07 CST 2024, time=2024-07-15, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2176663, encodeId=f7c121e666302, content=awaiting reviewer scores 后11天后变成了Awaiting SE Recommendation ,拒的可能性大吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bbb4799156, createdName=2606467171, createdTime=Sat Dec 23 10:23:14 CST 2023, time=2023-12-23, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1216555, encodeId=ba5d121655554, content=投稿命中率:25.0<br>偏重的研究方向:血液<br>经验分享:我投稿8天了,依然处于Awaiting Admin Processing,稿号TH-22-04-0201<br>不知道是否正常,你们都啥情况?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b2e2216153, createdName=120e7c52m79(暂无昵称), createdTime=Tue May 03 14:04:00 CST 2022, time=2022-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224943, encodeId=bede122494364, content=投稿命中率:50.0<br>偏重的研究方向:心血管医学<br>经验分享:5月24号投稿,到现在Awaiting EIC Decision已经快10天了,是不是没戏了。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc5b5422035, createdName=ms8000000183735007, createdTime=Tue Jun 07 12:45:03 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2166341, encodeId=fbc72166341ba, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:静脉血栓;孟德尔随机化<br>经验分享:Submit:30-Jul-2023<br>Major Revision:27-Aug-2023<br>Minor Revision:18-Oct-2023<br>Accept:26-Oct-2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220102/e596621ff7ca4602b0af813517c72811/c6ec383c45484fd78c6ed80849d0e129.jpg, createdBy=81935632595, createdName=一步之遥、, createdTime=Thu Nov 02 18:29:17 CST 2023, time=2023-11-02, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1098101, encodeId=ebeb109810186, content=模型图对审稿人对稿件的态度是有利还是不利?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098102, encodeId=0f67109810229, content=实验数据被抢先发表了怎么办?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=839911, encodeId=0f558399117c, content=2次大修后再一次小修,小修返回后第二天被接收了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dee5413979, createdName=ms4391593229390302, createdTime=Fri Dec 15 19:21:28 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548925, encodeId=fa0554892581, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:一审一个月,共两个Review,审稿人意见比较苛刻,重视体内数据和临床意义,是ESC血栓和动脉粥样硬化工作组的官方杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=367, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da2b2190065, createdName=peterread, createdTime=Sun Nov 05 18:26:00 CST 2017, time=2017-11-05, status=1, ipAttribution=)]
    2023-11-02 一步之遥、 来自浙江省

    审稿速度:3.0 | 投稿命中率:75.0
    偏重的研究方向:静脉血栓;孟德尔随机化
    经验分享:Submit:30-Jul-2023
    Major Revision:27-Aug-2023
    Minor Revision:18-Oct-2023
    Accept:26-Oct-2023

    7

    展开7条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2215159, encodeId=9ade22151598a, content=从awaiting reviewer assignment直接变成awaiting EIC decision,没有收到审稿人的意见就变成主编决定了,很忐忑呐!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc729386750, createdName=ms6000000193292497, createdTime=Mon Jul 15 23:19:18 CST 2024, time=2024-07-15, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2215155, encodeId=63d2221515568, content=有朋友遇到过从awaiting reviewer assignment 直接变成awaiting EIC decision 的情况吗?按理来说应该是要分配审稿人的,但是没有收到审稿意见直接变成主编决定,非常忐忑不安呐!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ae25440471, createdName=ms7000002143451046, createdTime=Mon Jul 15 23:08:07 CST 2024, time=2024-07-15, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2176663, encodeId=f7c121e666302, content=awaiting reviewer scores 后11天后变成了Awaiting SE Recommendation ,拒的可能性大吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bbb4799156, createdName=2606467171, createdTime=Sat Dec 23 10:23:14 CST 2023, time=2023-12-23, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1216555, encodeId=ba5d121655554, content=投稿命中率:25.0<br>偏重的研究方向:血液<br>经验分享:我投稿8天了,依然处于Awaiting Admin Processing,稿号TH-22-04-0201<br>不知道是否正常,你们都啥情况?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b2e2216153, createdName=120e7c52m79(暂无昵称), createdTime=Tue May 03 14:04:00 CST 2022, time=2022-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224943, encodeId=bede122494364, content=投稿命中率:50.0<br>偏重的研究方向:心血管医学<br>经验分享:5月24号投稿,到现在Awaiting EIC Decision已经快10天了,是不是没戏了。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc5b5422035, createdName=ms8000000183735007, createdTime=Tue Jun 07 12:45:03 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2166341, encodeId=fbc72166341ba, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:静脉血栓;孟德尔随机化<br>经验分享:Submit:30-Jul-2023<br>Major Revision:27-Aug-2023<br>Minor Revision:18-Oct-2023<br>Accept:26-Oct-2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220102/e596621ff7ca4602b0af813517c72811/c6ec383c45484fd78c6ed80849d0e129.jpg, createdBy=81935632595, createdName=一步之遥、, createdTime=Thu Nov 02 18:29:17 CST 2023, time=2023-11-02, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1098101, encodeId=ebeb109810186, content=模型图对审稿人对稿件的态度是有利还是不利?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098102, encodeId=0f67109810229, content=实验数据被抢先发表了怎么办?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=839911, encodeId=0f558399117c, content=2次大修后再一次小修,小修返回后第二天被接收了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dee5413979, createdName=ms4391593229390302, createdTime=Fri Dec 15 19:21:28 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548925, encodeId=fa0554892581, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:一审一个月,共两个Review,审稿人意见比较苛刻,重视体内数据和临床意义,是ESC血栓和动脉粥样硬化工作组的官方杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=367, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da2b2190065, createdName=peterread, createdTime=Sun Nov 05 18:26:00 CST 2017, time=2017-11-05, status=1, ipAttribution=)]
    2021-12-28 MS68862005

    模型图对审稿人对稿件的态度是有利还是不利?

    1

    展开1条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2215159, encodeId=9ade22151598a, content=从awaiting reviewer assignment直接变成awaiting EIC decision,没有收到审稿人的意见就变成主编决定了,很忐忑呐!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc729386750, createdName=ms6000000193292497, createdTime=Mon Jul 15 23:19:18 CST 2024, time=2024-07-15, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2215155, encodeId=63d2221515568, content=有朋友遇到过从awaiting reviewer assignment 直接变成awaiting EIC decision 的情况吗?按理来说应该是要分配审稿人的,但是没有收到审稿意见直接变成主编决定,非常忐忑不安呐!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ae25440471, createdName=ms7000002143451046, createdTime=Mon Jul 15 23:08:07 CST 2024, time=2024-07-15, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2176663, encodeId=f7c121e666302, content=awaiting reviewer scores 后11天后变成了Awaiting SE Recommendation ,拒的可能性大吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bbb4799156, createdName=2606467171, createdTime=Sat Dec 23 10:23:14 CST 2023, time=2023-12-23, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1216555, encodeId=ba5d121655554, content=投稿命中率:25.0<br>偏重的研究方向:血液<br>经验分享:我投稿8天了,依然处于Awaiting Admin Processing,稿号TH-22-04-0201<br>不知道是否正常,你们都啥情况?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b2e2216153, createdName=120e7c52m79(暂无昵称), createdTime=Tue May 03 14:04:00 CST 2022, time=2022-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224943, encodeId=bede122494364, content=投稿命中率:50.0<br>偏重的研究方向:心血管医学<br>经验分享:5月24号投稿,到现在Awaiting EIC Decision已经快10天了,是不是没戏了。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc5b5422035, createdName=ms8000000183735007, createdTime=Tue Jun 07 12:45:03 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2166341, encodeId=fbc72166341ba, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:静脉血栓;孟德尔随机化<br>经验分享:Submit:30-Jul-2023<br>Major Revision:27-Aug-2023<br>Minor Revision:18-Oct-2023<br>Accept:26-Oct-2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220102/e596621ff7ca4602b0af813517c72811/c6ec383c45484fd78c6ed80849d0e129.jpg, createdBy=81935632595, createdName=一步之遥、, createdTime=Thu Nov 02 18:29:17 CST 2023, time=2023-11-02, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1098101, encodeId=ebeb109810186, content=模型图对审稿人对稿件的态度是有利还是不利?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098102, encodeId=0f67109810229, content=实验数据被抢先发表了怎么办?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=839911, encodeId=0f558399117c, content=2次大修后再一次小修,小修返回后第二天被接收了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dee5413979, createdName=ms4391593229390302, createdTime=Fri Dec 15 19:21:28 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548925, encodeId=fa0554892581, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:一审一个月,共两个Review,审稿人意见比较苛刻,重视体内数据和临床意义,是ESC血栓和动脉粥样硬化工作组的官方杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=367, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da2b2190065, createdName=peterread, createdTime=Sun Nov 05 18:26:00 CST 2017, time=2017-11-05, status=1, ipAttribution=)]
    2021-12-27 ms6000000264964247

    实验数据被抢先发表了怎么办?

    1

    展开1条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2215159, encodeId=9ade22151598a, content=从awaiting reviewer assignment直接变成awaiting EIC decision,没有收到审稿人的意见就变成主编决定了,很忐忑呐!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc729386750, createdName=ms6000000193292497, createdTime=Mon Jul 15 23:19:18 CST 2024, time=2024-07-15, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2215155, encodeId=63d2221515568, content=有朋友遇到过从awaiting reviewer assignment 直接变成awaiting EIC decision 的情况吗?按理来说应该是要分配审稿人的,但是没有收到审稿意见直接变成主编决定,非常忐忑不安呐!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ae25440471, createdName=ms7000002143451046, createdTime=Mon Jul 15 23:08:07 CST 2024, time=2024-07-15, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2176663, encodeId=f7c121e666302, content=awaiting reviewer scores 后11天后变成了Awaiting SE Recommendation ,拒的可能性大吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bbb4799156, createdName=2606467171, createdTime=Sat Dec 23 10:23:14 CST 2023, time=2023-12-23, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1216555, encodeId=ba5d121655554, content=投稿命中率:25.0<br>偏重的研究方向:血液<br>经验分享:我投稿8天了,依然处于Awaiting Admin Processing,稿号TH-22-04-0201<br>不知道是否正常,你们都啥情况?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b2e2216153, createdName=120e7c52m79(暂无昵称), createdTime=Tue May 03 14:04:00 CST 2022, time=2022-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224943, encodeId=bede122494364, content=投稿命中率:50.0<br>偏重的研究方向:心血管医学<br>经验分享:5月24号投稿,到现在Awaiting EIC Decision已经快10天了,是不是没戏了。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc5b5422035, createdName=ms8000000183735007, createdTime=Tue Jun 07 12:45:03 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2166341, encodeId=fbc72166341ba, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:静脉血栓;孟德尔随机化<br>经验分享:Submit:30-Jul-2023<br>Major Revision:27-Aug-2023<br>Minor Revision:18-Oct-2023<br>Accept:26-Oct-2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220102/e596621ff7ca4602b0af813517c72811/c6ec383c45484fd78c6ed80849d0e129.jpg, createdBy=81935632595, createdName=一步之遥、, createdTime=Thu Nov 02 18:29:17 CST 2023, time=2023-11-02, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1098101, encodeId=ebeb109810186, content=模型图对审稿人对稿件的态度是有利还是不利?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098102, encodeId=0f67109810229, content=实验数据被抢先发表了怎么办?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=839911, encodeId=0f558399117c, content=2次大修后再一次小修,小修返回后第二天被接收了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dee5413979, createdName=ms4391593229390302, createdTime=Fri Dec 15 19:21:28 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548925, encodeId=fa0554892581, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:一审一个月,共两个Review,审稿人意见比较苛刻,重视体内数据和临床意义,是ESC血栓和动脉粥样硬化工作组的官方杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=367, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da2b2190065, createdName=peterread, createdTime=Sun Nov 05 18:26:00 CST 2017, time=2017-11-05, status=1, ipAttribution=)]
    2017-12-15 ms4391593229390302

    2次大修后再一次小修,小修返回后第二天被接收了

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2215159, encodeId=9ade22151598a, content=从awaiting reviewer assignment直接变成awaiting EIC decision,没有收到审稿人的意见就变成主编决定了,很忐忑呐!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc729386750, createdName=ms6000000193292497, createdTime=Mon Jul 15 23:19:18 CST 2024, time=2024-07-15, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2215155, encodeId=63d2221515568, content=有朋友遇到过从awaiting reviewer assignment 直接变成awaiting EIC decision 的情况吗?按理来说应该是要分配审稿人的,但是没有收到审稿意见直接变成主编决定,非常忐忑不安呐!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ae25440471, createdName=ms7000002143451046, createdTime=Mon Jul 15 23:08:07 CST 2024, time=2024-07-15, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2176663, encodeId=f7c121e666302, content=awaiting reviewer scores 后11天后变成了Awaiting SE Recommendation ,拒的可能性大吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bbb4799156, createdName=2606467171, createdTime=Sat Dec 23 10:23:14 CST 2023, time=2023-12-23, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1216555, encodeId=ba5d121655554, content=投稿命中率:25.0<br>偏重的研究方向:血液<br>经验分享:我投稿8天了,依然处于Awaiting Admin Processing,稿号TH-22-04-0201<br>不知道是否正常,你们都啥情况?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b2e2216153, createdName=120e7c52m79(暂无昵称), createdTime=Tue May 03 14:04:00 CST 2022, time=2022-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224943, encodeId=bede122494364, content=投稿命中率:50.0<br>偏重的研究方向:心血管医学<br>经验分享:5月24号投稿,到现在Awaiting EIC Decision已经快10天了,是不是没戏了。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc5b5422035, createdName=ms8000000183735007, createdTime=Tue Jun 07 12:45:03 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2166341, encodeId=fbc72166341ba, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:静脉血栓;孟德尔随机化<br>经验分享:Submit:30-Jul-2023<br>Major Revision:27-Aug-2023<br>Minor Revision:18-Oct-2023<br>Accept:26-Oct-2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220102/e596621ff7ca4602b0af813517c72811/c6ec383c45484fd78c6ed80849d0e129.jpg, createdBy=81935632595, createdName=一步之遥、, createdTime=Thu Nov 02 18:29:17 CST 2023, time=2023-11-02, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1098101, encodeId=ebeb109810186, content=模型图对审稿人对稿件的态度是有利还是不利?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098102, encodeId=0f67109810229, content=实验数据被抢先发表了怎么办?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=839911, encodeId=0f558399117c, content=2次大修后再一次小修,小修返回后第二天被接收了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dee5413979, createdName=ms4391593229390302, createdTime=Fri Dec 15 19:21:28 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548925, encodeId=fa0554892581, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:一审一个月,共两个Review,审稿人意见比较苛刻,重视体内数据和临床意义,是ESC血栓和动脉粥样硬化工作组的官方杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=367, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da2b2190065, createdName=peterread, createdTime=Sun Nov 05 18:26:00 CST 2017, time=2017-11-05, status=1, ipAttribution=)]
    2017-11-05 peterread

    审稿速度:1.0 | 投稿命中率:25.0
    经验分享:一审一个月,共两个Review,审稿人意见比较苛刻,重视体内数据和临床意义,是ESC血栓和动脉粥样硬化工作组的官方杂志

    0

共45条页码: 1/5页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分